NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses

Andreas Wadle, Axel Mischo, Sabine Strahl, Hiroyoshi Nishikawa, Gerhard Held, Frank Neumann, Beate Wullner, Eliane Fischer, Sascha Kleber, Julia Karbach, Elke Jager, Hiroshi Shiku, Kunle Odunsi, Protul A. Shrikant, Alexander Knuth, Vincenzo Cerundolo, Christoph Renner

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Vaccine strategies that target dendritic cells to elicit potent cellular immunity are the subject of intense research. Here we report that the genetically engineered yeast Saccharomyces cerevisiae, expressing the full-length tumour-associated antigen NY-ESO-1, is a versatile host for protein production. Exposing dendritic cells (DCs) to soluble NY-ESO-1 protein linked to the yeast a-agglutinin 2 protein (Aga2p) protein resulted in protein uptake, processing and MHC class I cross-presentation of NY-ESO-1-derived peptides. The process of antigen uptake and cross-presentation was dependent on the glycosylation pattern of NY-ESO-1-Aga2p protein and the presence of accessible mannose receptors. In addition, NY-ESO-1-Aga2p protein uptake by dendritic cells resulted in recognition by HLA-DP4 NY-ESO-1-specific CD4+ T cells, indicating MHC class II presentation. Finally, vaccination of mice with yeast-derived NY-ESO-1-Aga2p protein led to an enhanced humoral and cellular immune response, when compared to the bacterially expressed NY-ESO-1 protein. Together, these data demonstrate that yeast-derived full-length NY-ESO-1-Aga2p protein is processed and presented efficiently by MHC class I and II complexes and warrants clinical trials to determine the potential value of S. cerevisiae as a host for cancer vaccine development.

Original languageEnglish (US)
Pages (from-to)919-931
Number of pages13
JournalYeast
Volume27
Issue number11
DOIs
StatePublished - Nov 2010
Externally publishedYes

Fingerprint

Fungal Proteins
Yeast
Proteins
Yeasts
Cross-Priming
Dendritic Cells
Vaccines
Antigens
Cellular Immunity
Saccharomyces cerevisiae
Glycosylation
Cancer Vaccines
T-cells
Agglutinins
Neoplasm Antigens
Humoral Immunity
Peptides
Tumors
Vaccination
Clinical Trials

Keywords

  • Cross-presentation
  • Cytotoxic T cells
  • Glycosylation
  • MHC
  • Peptide processing
  • Presentation
  • Yeast

ASJC Scopus subject areas

  • Biochemistry
  • Biotechnology
  • Genetics
  • Bioengineering
  • Applied Microbiology and Biotechnology

Cite this

Wadle, A., Mischo, A., Strahl, S., Nishikawa, H., Held, G., Neumann, F., ... Renner, C. (2010). NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses. Yeast, 27(11), 919-931. https://doi.org/10.1002/yea.1796

NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses. / Wadle, Andreas; Mischo, Axel; Strahl, Sabine; Nishikawa, Hiroyoshi; Held, Gerhard; Neumann, Frank; Wullner, Beate; Fischer, Eliane; Kleber, Sascha; Karbach, Julia; Jager, Elke; Shiku, Hiroshi; Odunsi, Kunle; Shrikant, Protul A.; Knuth, Alexander; Cerundolo, Vincenzo; Renner, Christoph.

In: Yeast, Vol. 27, No. 11, 11.2010, p. 919-931.

Research output: Contribution to journalArticle

Wadle, A, Mischo, A, Strahl, S, Nishikawa, H, Held, G, Neumann, F, Wullner, B, Fischer, E, Kleber, S, Karbach, J, Jager, E, Shiku, H, Odunsi, K, Shrikant, PA, Knuth, A, Cerundolo, V & Renner, C 2010, 'NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses', Yeast, vol. 27, no. 11, pp. 919-931. https://doi.org/10.1002/yea.1796
Wadle A, Mischo A, Strahl S, Nishikawa H, Held G, Neumann F et al. NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses. Yeast. 2010 Nov;27(11):919-931. https://doi.org/10.1002/yea.1796
Wadle, Andreas ; Mischo, Axel ; Strahl, Sabine ; Nishikawa, Hiroyoshi ; Held, Gerhard ; Neumann, Frank ; Wullner, Beate ; Fischer, Eliane ; Kleber, Sascha ; Karbach, Julia ; Jager, Elke ; Shiku, Hiroshi ; Odunsi, Kunle ; Shrikant, Protul A. ; Knuth, Alexander ; Cerundolo, Vincenzo ; Renner, Christoph. / NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses. In: Yeast. 2010 ; Vol. 27, No. 11. pp. 919-931.
@article{44d4304f86cd46548ae317bc73423253,
title = "NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses",
abstract = "Vaccine strategies that target dendritic cells to elicit potent cellular immunity are the subject of intense research. Here we report that the genetically engineered yeast Saccharomyces cerevisiae, expressing the full-length tumour-associated antigen NY-ESO-1, is a versatile host for protein production. Exposing dendritic cells (DCs) to soluble NY-ESO-1 protein linked to the yeast a-agglutinin 2 protein (Aga2p) protein resulted in protein uptake, processing and MHC class I cross-presentation of NY-ESO-1-derived peptides. The process of antigen uptake and cross-presentation was dependent on the glycosylation pattern of NY-ESO-1-Aga2p protein and the presence of accessible mannose receptors. In addition, NY-ESO-1-Aga2p protein uptake by dendritic cells resulted in recognition by HLA-DP4 NY-ESO-1-specific CD4+ T cells, indicating MHC class II presentation. Finally, vaccination of mice with yeast-derived NY-ESO-1-Aga2p protein led to an enhanced humoral and cellular immune response, when compared to the bacterially expressed NY-ESO-1 protein. Together, these data demonstrate that yeast-derived full-length NY-ESO-1-Aga2p protein is processed and presented efficiently by MHC class I and II complexes and warrants clinical trials to determine the potential value of S. cerevisiae as a host for cancer vaccine development.",
keywords = "Cross-presentation, Cytotoxic T cells, Glycosylation, MHC, Peptide processing, Presentation, Yeast",
author = "Andreas Wadle and Axel Mischo and Sabine Strahl and Hiroyoshi Nishikawa and Gerhard Held and Frank Neumann and Beate Wullner and Eliane Fischer and Sascha Kleber and Julia Karbach and Elke Jager and Hiroshi Shiku and Kunle Odunsi and Shrikant, {Protul A.} and Alexander Knuth and Vincenzo Cerundolo and Christoph Renner",
year = "2010",
month = "11",
doi = "10.1002/yea.1796",
language = "English (US)",
volume = "27",
pages = "919--931",
journal = "Yeast",
issn = "0749-503X",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses

AU - Wadle, Andreas

AU - Mischo, Axel

AU - Strahl, Sabine

AU - Nishikawa, Hiroyoshi

AU - Held, Gerhard

AU - Neumann, Frank

AU - Wullner, Beate

AU - Fischer, Eliane

AU - Kleber, Sascha

AU - Karbach, Julia

AU - Jager, Elke

AU - Shiku, Hiroshi

AU - Odunsi, Kunle

AU - Shrikant, Protul A.

AU - Knuth, Alexander

AU - Cerundolo, Vincenzo

AU - Renner, Christoph

PY - 2010/11

Y1 - 2010/11

N2 - Vaccine strategies that target dendritic cells to elicit potent cellular immunity are the subject of intense research. Here we report that the genetically engineered yeast Saccharomyces cerevisiae, expressing the full-length tumour-associated antigen NY-ESO-1, is a versatile host for protein production. Exposing dendritic cells (DCs) to soluble NY-ESO-1 protein linked to the yeast a-agglutinin 2 protein (Aga2p) protein resulted in protein uptake, processing and MHC class I cross-presentation of NY-ESO-1-derived peptides. The process of antigen uptake and cross-presentation was dependent on the glycosylation pattern of NY-ESO-1-Aga2p protein and the presence of accessible mannose receptors. In addition, NY-ESO-1-Aga2p protein uptake by dendritic cells resulted in recognition by HLA-DP4 NY-ESO-1-specific CD4+ T cells, indicating MHC class II presentation. Finally, vaccination of mice with yeast-derived NY-ESO-1-Aga2p protein led to an enhanced humoral and cellular immune response, when compared to the bacterially expressed NY-ESO-1 protein. Together, these data demonstrate that yeast-derived full-length NY-ESO-1-Aga2p protein is processed and presented efficiently by MHC class I and II complexes and warrants clinical trials to determine the potential value of S. cerevisiae as a host for cancer vaccine development.

AB - Vaccine strategies that target dendritic cells to elicit potent cellular immunity are the subject of intense research. Here we report that the genetically engineered yeast Saccharomyces cerevisiae, expressing the full-length tumour-associated antigen NY-ESO-1, is a versatile host for protein production. Exposing dendritic cells (DCs) to soluble NY-ESO-1 protein linked to the yeast a-agglutinin 2 protein (Aga2p) protein resulted in protein uptake, processing and MHC class I cross-presentation of NY-ESO-1-derived peptides. The process of antigen uptake and cross-presentation was dependent on the glycosylation pattern of NY-ESO-1-Aga2p protein and the presence of accessible mannose receptors. In addition, NY-ESO-1-Aga2p protein uptake by dendritic cells resulted in recognition by HLA-DP4 NY-ESO-1-specific CD4+ T cells, indicating MHC class II presentation. Finally, vaccination of mice with yeast-derived NY-ESO-1-Aga2p protein led to an enhanced humoral and cellular immune response, when compared to the bacterially expressed NY-ESO-1 protein. Together, these data demonstrate that yeast-derived full-length NY-ESO-1-Aga2p protein is processed and presented efficiently by MHC class I and II complexes and warrants clinical trials to determine the potential value of S. cerevisiae as a host for cancer vaccine development.

KW - Cross-presentation

KW - Cytotoxic T cells

KW - Glycosylation

KW - MHC

KW - Peptide processing

KW - Presentation

KW - Yeast

UR - http://www.scopus.com/inward/record.url?scp=78149355995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149355995&partnerID=8YFLogxK

U2 - 10.1002/yea.1796

DO - 10.1002/yea.1796

M3 - Article

VL - 27

SP - 919

EP - 931

JO - Yeast

JF - Yeast

SN - 0749-503X

IS - 11

ER -